ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dupilumab

Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageDupilumab: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 16, 201993 company-led studies, 14 open or runningNext primary completion: Feb 7, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only529 open or runningphase 4since Jul 16, 2019Mar 9, 2011Feb 7, 2027phase 4 · NCT07905547
Regeneron Pharmaceuticals404 open or runningphase 4since Dec 17, 2019Nov 10, 2009Apr 24, 2027phase 4 · NCT06572228
Andover Eye Associatesits history only11 open or runningphase 2since Mar 2, 2020Mar 2, 2020none ahead

Also a collaborator on its studies: Aimmune Therapeutics and Statistics & Data.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since Nov 10, 2009.

  1. Sep 21, 2018Phase 2 study in Peanut HypersensitivityNCT03682770 · 148 enrolled · United States
  2. Nov 7, 2018Phase 2 study in Dermatitis, AtopicNCT03736967 · 206 enrolled · United States, Belgium, Czechia and more
  3. Jan 2, 2019Phase 2 study in Peanut HypersensitivityNCT03793608 · 25 enrolled · United States, Canada
  4. Dec 17, 2019Phase 4 study in AsthmaNCT04203797 · 40 enrolled · United States, France, Germany and more
  5. Dec 18, 2019Phase 3 study in Pemphigoid, BullousNCT04206553 · 106 enrolled · United States, Australia, France and more
  6. May 7, 2020Phase 3 study in Eosinophilic EsophagitisNCT04394351 · 102 enrolled · United States, Canada
  7. Jun 2, 2020Phase 3 study in Moderate to Severe Atopic Hand and Foot DermatitisNCT04417894 · 133 enrolled · United States, Germany, Japan and more
  8. Jun 4, 2020Phase 2 study in Aspergillosis, Allergic BronchopulmonaryNCT04442269 · 62 enrolled · United States, Bulgaria, France and more
  9. Oct 18, 2022Phase 4 study in Dermatitis, AtopicNCT05590585 · 124 enrolled · United States
  10. Apr 14, 2023Phase 2 study in Eosinophilic enteropathyNCT05831176 · 22 enrolled · United States, Canada, Italy and more
  11. Aug 23, 2024Phase 4 study in AsthmaNCT06572228 · 120 enrolled · United States, Canada, Denmark and more
  12. Aug 1, 2025Phase 3 study in Eosinophilic EsophagitisNCT07112378 · 20 planned · United States
  13. Sep 15, 2025Phase 4 study in Dermatitis, AtopicNCT07187089
  14. May 8, 2026Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07587658 · 754 planned · United States

Ahead

  1. Apr 24, 2027Primary completion: phase 4 study in AsthmaNCT06572228
  2. Jun 19, 2028Primary completion: phase 3 study in Eosinophilic EsophagitisNCT07112378
  3. Jul 30, 2028Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07587658

TargetBeta

IL4R →read by rule
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
drotokibartJiangsu HengRui Medicinephase 38
TQH2722Sino Biopharmaceuticalphase 37
SHR-1819Jiangsu HengRui Medicinephase 35

Studies

All 40 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07587658Pulmonary Disease, Chronic Obstructive · United States4RecruitingJul 30, 2028754
NCT07187089Dermatitis, Atopic4WithdrawnDec 23, 20270
NCT07112378Eosinophilic Esophagitis · United States3RecruitingJun 19, 202820
NCT06572228Asthma · United States, Canada, Denmark and more4Active, not recruitingApr 24, 2027120
NCT05831176Eosinophilic enteropathy · United States, Canada, Italy and more2Active, not recruitingFeb 23, 202622
NCT05590585Dermatitis, Atopic · United States4CompletedNov 14, 2024124
NCT04442269Aspergillosis, Allergic Bronchopulmonary · United States, Bulgaria, France and more2CompletedJul 27, 202362
NCT04417894Moderate to Severe Atopic Hand and Foot Dermatitis · United States, Germany, Japan and more3CompletedAug 31, 2022133
NCT04394351Eosinophilic Esophagitis · United States, Canada3CompletedJun 2, 2022102
NCT04206553Pemphigoid, Bullous · United States, Australia, France and more3CompletedJul 12, 2024106
NCT04203797Asthma · United States, France, Germany and more4CompletedJul 15, 202340
NCT03793608Peanut Hypersensitivity · United States, Canada2CompletedFeb 19, 202125
NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more2TerminatedMar 13, 2020206
NCT03682770Peanut Hypersensitivity · United States2CompletedOct 16, 2020148
NCT03633617Eosinophilic Esophagitis · United States, Australia, Belgium and more3CompletedSep 9, 2021321
NCT03558997Rhinitis, Allergic · United States, Canada2CompletedMay 14, 2019103
NCT03345914Dermatitis, Atopic · United States, Canada, Czechia and more3CompletedJun 20, 2019367
NCT03112577Asthma · United States, United Kingdom1CompletedMar 20, 201932
NCT03054428Dermatitis, Atopic · United States, Canada3CompletedApr 4, 2018251
NCT03050151Dermatitis, Atopic · United States1CompletedNov 14, 2017176
NCT03346434Dermatitis, Atopic · United States, Germany, Poland and more3CompletedJul 8, 2021202
NCT02755649Dermatitis, Atopic · Austria, Belgium, Germany and more3CompletedJan 4, 2017325
NCT02647086Dermatitis, Atopic · United States1CompletedJul 201614
NCT02612454Dermatitis, Atopic · United States, Canada, Czechia and more3CompletedOct 9, 2026880
NCT02407756Dermatitis, Atopic · Canada, Czechia, Germany and more2CompletedMar 31, 201678
NCT02395133Dermatitis, Atopic3CompletedJul 2016422
NCT02379052Eosinophilic Esophagitis · United States2CompletedFeb 17, 201747
NCT02277769Dermatitis, Atopic · United States, Canada, France and more3CompletedOct 31, 2015708
NCT02277743Dermatitis, Atopic · United States, Bulgaria, Canada and more3CompletedNov 2015671
NCT02260986Dermatitis, Atopic · United States, Australia, Canada and more3CompletedAug 2015740
NCT02210780Dermatitis, Atopic · United States2CompletedSep 15, 2015194
NCT01979016Dermatitis, Atopic · United States, Canada2CompletedDec 31, 201454
NCT01949311Dermatitis, Atopic · United States, Australia, Austria and more3CompletedJun 27, 20222,733
NCT01859988Dermatitis, Atopic · United States, Canada, Czechia and more2CompletedMay 2014380
NCT01639040Dermatitis, Atopic · Germany, Hungary, Poland2CompletedDec 201231
NCT01548404Dermatitis, Atopic · Czechia, France, Germany and more2CompletedMar 2013109
NCT01484600Healthy · United States1CompletedFeb 201236
NCT01385657Dermatitis, Atopic · Australia, Germany, New Zealand1CompletedMar 31, 201237
NCT01259323Dermatitis · United States1CompletedJul 201230
NCT01015027Healthy · United States1CompletedJul 201048

How it is read

Names in the registry

  • “Dupilumab”, 55 entries
  • “Dupilumab SAR231893”, 13 entries
  • “dupilumab”, 10 entries
  • “Dupilumab (SAR231893)”, 5 entries
  • “REGN668”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.